Biotech News
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
Late-breaking oral presentation will highlight initial clinical results evaluating azer-cel, an allogeneic “off-the-shelf” CD19-directed CAR T-cell therapy, in patients with progressive multiple sclerosis Additional presentations include Phase 3 ENHANCE data supporting the investigational BRIUMVI
